These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22354221)

  • 1. Crizotinib (xalkori) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2012 Feb; 54(1383):11-2. PubMed ID: 22354221
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib.
    Shaw AT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Dec; 10(12):897-8. PubMed ID: 22129984
    [No Abstract]   [Full Text] [Related]  

  • 6. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 12. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 14. First-line crizotinib shows promise in patients with NSCLC.
    Bagcchi S
    Lancet Respir Med; 2015 Jan; 3(1):17. PubMed ID: 25497281
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for lung cancer.
    Petrosyan F; Daw H; Haddad A; Spiro T
    Anticancer Drugs; 2012 Nov; 23(10):1016-21. PubMed ID: 22932130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Solomon BJ
    N Engl J Med; 2015 Feb; 372(7):683-4. PubMed ID: 25671264
    [No Abstract]   [Full Text] [Related]  

  • 18. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Arnaoutakis K
    N Engl J Med; 2015 Feb; 372(7):683. PubMed ID: 25671265
    [No Abstract]   [Full Text] [Related]  

  • 19. In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
    Veeramachaneni N; Wigle D; Boughey JC
    Bull Am Coll Surg; 2017 Mar; 102(3):37-8. PubMed ID: 28920661
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacology profile of crizotinib (Xalkori(®)Capsules) and clinical findings on this drug].
    Nonaka S; Yamaguchi S; Nagasawa T; Tahara M
    Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):106-13. PubMed ID: 23391552
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.